



April 15, 2005

Celsion Corporation to Present at White Mountain Capital's Third Annual Biotechnology Conference

COLUMBIA, Md., April 15 /PRNewswire-FirstCall/ -- CELSION CORPORATION (Amex: CLN) today announced that Tony Deasey, Executive Vice President, will present at White Mountain Capital's Third Annual Biotechnology Conference at the Rihga Royal Hotel, New York City on Tuesday, April 19 at 3:30 p.m. local time.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: <http://www.celsion.com>

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

SOURCE Celsion Corporation

-0-

04/15/2005

/CONTACT: Tony Deasey of Celsion Corporation, +1-410-290-5390, or tony@celsion.com; General Info: Marilyn Meek, +1-212-827-3773, mmEEK@financialrelationsboard.com, Investor Info: Susan Garland, +1-212-827-3775, sgarland@financialrelationsboard.com, both of Financial Relations Board, for Celsion Corporation/
/Web site: <http://www.celsion.com> /
(CLN)

CO: Celsion Corporation
ST: Maryland, New York
IN: HEA MTC BIO
SU: TDS

AA

-- NYF023 --

0770 04/15/2005 10:00 EDT <http://www.prnewswire.com>